Agreement on Antipsychotic Drug
Budapest - Hungarian Gedeon Richter's atypical antipsychotic RGH-188 and related compounds are at the centre of a recently signed collaboration agreement between Gedeon Richter Ltd., its subsidiary Gedeon Richter USA Inc. and Forest Laboratories Ireland Ltd. RGH-188, an orally active D2/D3 antagonist in development for schizophrenia, bipolar mania and other psychia-tric conditions, has entered phase I trials in the UK. If phase I and phase II studies are successfully completed, the compound could possibly enter phase III in the US before the end of 2006. Pre-clinical studies suggest that the product will be active, well tolerated and have a lower potential to cause adverse events associated with this therapeutic class. RGH-188 is claimed by a patent application which, if issued, will expire in 2024. Forest will pay Richter an upfront payment and other milestones if the development and commercialization of the product are successfully completed in Forest's territory. The parties will jointly collaborate on and fund the development of the product.